CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 05/11/23

2023-05-11 19:59:08 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu...

2023-05-11 16:49:41 ET Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q1 GAAP EPS of -$0.47 beats by $0.19 . As of March 31, 2023, pro forma cash and cash equivalents totaled $16.1 million, including the $4.7 million of United Kingdom research &...

- Key Catalysts ahead with multiple Value Generating Readouts - - Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib - - Advancing single-agent Efficacy with Differentiated Oral Plogosertib - - Adds to Balance Sheet with non-dilutive $4.7 million fro...

2023-05-10 17:35:55 ET Major earnings expected after the bell on Thursday include: Petroleo Brasilerio SA Petrobars ( PBR ) Zomedica Corp. ( ZOM ) Asensus Surgical ( ASXC ) IAMGOLD Corporation ( IAG ) IonQ ( IONQ ) For further details see: ...

BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thurs...

2023-05-03 09:41:57 ET Cyclacel Pharmaceuticals ( NASDAQ: CYCC ) has announced that it received a payment of £3.9M ($4.7M) as a R&D tax credit from HMRC, the tax agency of the United Kingdom government. “We appreciate the UK government’s support as w...

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of £3.9 million (...

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in ...

2023-03-06 21:04:08 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Conference Call March 6, 2023 16:30 ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice Pres...

2023-03-06 16:20:30 ET Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q4 GAAP EPS of -$0.60 misses by $0.12 . Report final data from dose escalation stage and RP2D determination from the 065-101 study of oral fadraciclib in patients with advanced solid tumors...